Key statistics
On Friday, Beam Therapeutics Inc (BEAM:NSQ) closed at 23.41, 38.11% above the 52 week low of 16.95 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.50 |
---|---|
High | 23.73 |
Low | 22.95 |
Bid | 23.05 |
Offer | 23.55 |
Previous close | 22.94 |
Average volume | 763.01k |
---|---|
Shares outstanding | 82.42m |
Free float | 81.18m |
P/E (TTM) | -- |
Market cap | 1.93bn USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 21:00 BST.
More ▼
Announcements
- Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
- Beam Therapeutics Announces Transition of Chief Financial Officer
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
More ▼